A Phase I, First-In-Human, Multiple Phase, Single and Multiple-Ascending Dose Study of TERN-201 in Healthy Human Participants
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs TERN 201 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors Terns Pharmaceuticals
- 13 Aug 2019 According to a Terns Pharmaceuticals media release, based on the interim results, the study has progressed to the multiple-dose phase.
- 13 Aug 2019 According to a Terns Pharmaceuticals media release, the company look forward to seeing further results from this study later in the year.
- 13 Aug 2019 Status changed from planning to recruiting, according to a Terns Pharmaceuticals media release.